Palm - paralemmin Gene
生物種: Rattus norvegicus
遺伝子タイプ: protein coding
遺伝子ID: 170673
Summary
Predicted to enable D3 Dopamine Receptor binding activity. Predicted to be involved in several processes, including cellular response to electrical stimulus; negative regulation of Adenylate Cyclase activity; and positive regulation of filopodium assembly. Predicted to act upstream of or within several processes, including adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; Cytoskeleton organization; and regulation of cell shape. Located in several cellular components, including apicolateral plasma membrane; basolateral plasma membrane; and dendritic spine membrane. Orthologous to human PALM (paralemmin). [provided by Alliance of Genome Resources, Apr 2022]
Palm Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_130829.2 | NP_570842.1 | paralemmin-1 |
| Biological Process GO Annotation | Evidence | 参考文献 | 由来 |
|---|---|---|---|
| involved in regulation of postsynapse assembly |
IDA
IDA: Inferred from direct assay
|
18287537 | RGD |
| involved in regulation of postsynapse assembly |
IMP
IMP: Inferred from mutant phenotype
|
18287537 | RGD |
| Cellular Component GO Annotation | Evidence | 参考文献 | 由来 |
|---|---|---|---|
| located in apicolateral plasma membrane |
IDA
IDA: Inferred from direct assay
|
16847661 | RGD |
| located in axon |
IDA
IDA: Inferred from direct assay
|
16847661 | RGD |
| located in basolateral plasma membrane |
IDA
IDA: Inferred from direct assay
|
16847661 | RGD |
| located in dendrite membrane |
IDA
IDA: Inferred from direct assay
|
16847661 | RGD |
| located in dendritic spine membrane |
IDA
IDA: Inferred from direct assay
|
16847661 | RGD |
| is active in glutamatergic synapse |
IDA
IDA: Inferred from direct assay
|
18287537 | RGD |
| is active in glutamatergic synapse |
IMP
IMP: Inferred from mutant phenotype
|
18287537 | RGD |
| located in plasma membrane |
IDA
IDA: Inferred from direct assay
|
16847661 | RGD |
| is active in postsynapse |
IDA
IDA: Inferred from direct assay
|
18287537 | RGD |
| is active in postsynapse |
IMP
IMP: Inferred from mutant phenotype
|
18287537 | RGD |
EXP: Inferred from Experiment
IDA: Inferred from direct assay
IPI: Inferred from physical interaction
IMP: Inferred from mutant phenotype
IGI: Inferred from genetic interaction
IEP: Inferred from expression pattern
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
paralemmin-1 |
|
Related Agents
- Clinical Phase
- Pre-clinical Phase
Clinical Phase
Bioactive Molecules
(4)
| 製品番号 | 製品名 |
製品効果
|
純度 |
Phase
|
|---|---|---|---|---|
| HY-170223 | Palm oil | / | Phase 4 | |
| HY-P10031 | SAR441255 | Agonist | 99.84% | Phase 1 |
| HY-120634 | BMS-929075 | Inhibitor | / | Phase 1 |
| HY-N2041S8 | Myristic acid-13C2 | / | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(55)
| 製品番号 | 製品名 |
製品効果
|
純度 |
Rare Diseases
|
|---|---|---|---|---|
| HY-N2041 | Myristic acid | 99.88% | Unkown | |
| HY-N0773 | Isovitexin | Inhibitor | 99.90% | Unkown |
| HY-N2041S | Myristic acid-d27 | 98.83% | Unkown | |
| HY-P10932A | pGk13a TFA | 96.92% | Unkown | |
| HY-108693 | β-Tocotrienol | Inducer | 99.14% | Unkown |
| HY-145519 | Mu-6S-Palm-β-Glc | 99.9% | Unkown | |
| HY-P0064 | Palmitoyl Tetrapeptide-3 | Inhibitor | 99.18% | Unkown |
| HY-W100026 | Galaxolide | 76.44% | Unkown | |
| HY-N2041S3 | Myristic acid-d3 | 98.62% | Unkown | |
| HY-148702 | di-Pal-MTO | 98.37% | Unkown | |
| HY-D1196 | Direct Blue 71 | / | Unkown | |
| HY-P10031A | SAR441255 TFA | Agonist | 99.93% | Unkown |
| HY-N2041S6 | Myristic acid-d5 | 98.0% | Unkown | |
| HY-W250170 | Decyl glucoside (60% in water) | / | Unkown | |
| HY-W013788 | 2-Palmitoylglycerol | Agonist | 99.0% | Unkown |
| HY-N2041S2 | Myristic acid-13C | 99.39% | Unkown | |
| HY-N2041S7 | Myristic acid-d7 | 99.80% | Unkown | |
| HY-P10380A | palm11-PrRP31 TFA | Agonist | 99.44% | Unkown |
| HY-W038795 | (S)-Ethyl lactate | 99.83% | Unkown | |
| HY-N2041S1 | Myristic acid-d2 | 98.0% | Unkown | |
| HY-N2041S4 | Myristic acid-13C3 | 99.9% | Unkown | |
| HY-W099600 | Lauric anhydride | 97.0% | Unkown | |
| HY-B0828 | Triazophos | Inhibitor | 99.25% | Unkown |
| HY-W111403 | Calcium oxide | 99.9% | Unkown | |
| HY-W585827 | 2-Chloro-1,3-propanediol | 99.56% | Unkown | |
| HY-128430 | Farnesyl acetate | Inhibitor | 90% | Unkown |
| HY-148701 | mono-Pal-MTO | / | Unkown | |
| HY-157172 | MorHap | Inhibitor | / | Unkown |
| HY-161909 | USP30-IN-1 | 99.41% | Unkown | |
| HY-D3157 | Photoactive esterase probe | / | Unkown | |
| HY-N19229 | Dihydrocitrinone | / | Unkown | |
| HY-N2041S5 | Myristic acid-d1 | / | Unkown | |
| HY-N20847 | Windmill palm leaves polysaccharides | / | Unkown | |
| HY-P10379 | palm-PrRP31 | Agonist | / | Unkown |
| HY-P10380 | palm11-PrRP31 | Agonist | / | Unkown |
| HY-P10932 | pGk13a | / | Unkown | |
| HY-RS10005 | PALM Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS10006 | PALM2AKAP2 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS10007 | PALM3 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W010736A | 1,2-Dipalmitoyl-rac-glycerol | / | Unkown | |
| HY-W585827S | 2-Chloro-1,3-propanediol-d5 | / | Unkown | |
| HY-W585827S1 | 2-Chloro-1,3-propanediol-d5 (major) | / | Unkown | |
| HY-W750719 | Neurosporene | / | Unkown | |
| HY-10467 | HCV-796 analog | Inhibitor | / | Unkown |
| HY-179357 | Hydrogenated palm oil | / | Unkown | |
| HY-179358 | Hydrogenated palm oil glycerides | / | Unkown | |
| HY-B0828S | Triazophos-d5 | Inhibitor | / | Unkown |
| HY-N7813 | 1,2-Dipalmitoyl-3-oleoylglycerol | / | Unkown | |
| HY-RS18489 | Palm Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS24971 | Palm Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W585827R | 2-Chloro-1,3-propanediol (Standard) | / | Unkown | |
| HY-W710399 | 2-Hydroxy-3-(palmitoyloxy)propyl stearate | / | Unkown | |
| HY-W710976 | 4-Methyl-5-nonanone | 98.47% | Unkown | |
| HY-W714197 | Methfuroxam | Inhibitor | / | Unkown |
| HY-W719989 | γ-Carotene | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service